Tearsheet
Investment Highlights Market Valuation Price Chart Business Description Interactive Breakdown Latest Trefis Analyses Better Bets vs. EW Recent Active Movers More From Trefis Peer Financials Peer Growth & Margins Peer Valuation Peer Returns Peer Analyses FDIC Bank Data Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Insider Activity Industry Resource Links External Quote Links

Edwards Lifesciences (EW)

Market Price (9/17/2025): $75.09 | Market Cap: $44.1 Bil
Sector: Health Care | Industry: Health Care Equipment

Edwards Lifesciences (EW)

Market Price (9/17/2025): $75.09
Market Cap: $44.1 Bil
Sector: Health Care
Industry: Health Care Equipment

Investment Highlights

0 Attractive yield
Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 9.4%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 4.9%		 Weak multi-year price returns
2Y Excs Rtn is -46%, 3Y Excs Rtn is -85%		 Expensive valuation multiples
P/EBITPrice/EBIT or Price/(Operating Income) ratio is 26x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 55x
1 Attractive operating margins
Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 28%		  
2 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 14%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 10%		  
3 Low stock price volatility
Vol 12M is 25%		  
0 Attractive yield
Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 9.4%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 4.9%
1 Attractive operating margins
Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 28%
2 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 14%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 10%
3 Low stock price volatility
Vol 12M is 25%
4 Weak multi-year price returns
2Y Excs Rtn is -46%, 3Y Excs Rtn is -85%
5 Expensive valuation multiples
P/EBITPrice/EBIT or Price/(Operating Income) ratio is 26x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 55x

Market Valuation

 9/17/252024202320222021
Share Price CYE$75.09$74.03$76.25$74.61$129.55
Market Cap CYE ($ Bil)44.143.746.145.780.9
Total Debt ($ Bil)0.70.70.70.70.7
Total Cash ($ Bil)4.14.01.61.21.5
Enterprise Value ($ Bil)40.744.446.846.481.6
Valuation Ratios     
P/S TTM7.88.19.210.315.4
P/EBIT TTM26.328.233.330.046.9
P/E TTM10.610.633.030.453.7
Sector Ratios     
P/S TTM (Sector)3.73.64.14.57.3
P/EBIT TTM (Sector)-1.6-1.3-1.4-1.3-2.9
P/E TTM (Sector)-1.8-1.5-1.5-1.3-2.9
 9/17/2520242023
Share Price CYE$75.09$74.03$76.25
Market Cap CYE ($ Bil)44.143.746.1
Total Debt ($ Bil)0.70.70.7
Total Cash ($ Bil)4.14.01.6
Enterprise Value ($ Bil)40.744.446.8
Valuation Ratios   
P/S TTM7.88.19.2
P/EBIT TTM26.328.233.3
P/E TTM10.610.633.0
Sector Ratios   
P/S TTM (Sector)3.73.64.1
P/EBIT TTM (Sector)-1.6-1.3-1.4
P/E TTM (Sector)-1.8-1.5-1.5

Market Cap Chart

Business Description

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. Show more

Price Returns Compared

Expand for Detailed View

 202020212022202320242025Total [1]
Returns
EW Return17%42%-42%2%-3%1%-0%
Peers Return3%6%-14%2%5%5%6%
S&P 500 Return16%27%-19%24%23%12%104%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: ABT, BSX, MDT, ZBH, BAX. See EW Returns vs. Peers.
[3] 2025 data is for the year up to 9/16/2025 (YTD)

Better Bets than Edwards Lifesciences (EW)

 EWBetter Performance than EW
MetricValueIndustry (Health Care Equipment)
Rev Chg LTM9.1%ISRG (20.8%), BSX (21.4%), SYK (11.4%), RMD (9.8%), DXCM (9.3%)
Rev Chg 3Y Avg3.0%ISRG (15.4%), BSX (14.6%), SYK (10.6%), MDT (3.3%), BDX (4.1%)
Op Mgn LTM27.9%ISRG (28.8%), IDXX (31.1%), RMD (32.8%), UTMD (33.3%)
CFO/Rev LTM14.0%ABT (21.0%), ISRG (30.9%), BSX (23.2%), SYK (20.0%), MDT (20.9%)
FCF/Rev LTM10.2%ABT (15.7%), ISRG (21.8%), BSX (17.5%), SYK (16.9%), MDT (15.5%)
Total Yield9.4%EMBC (13.4%)
 EWBetter Performance than EW
MetricValueAll Other Sectors
Rev Chg LTM9.1%NVDA (71.6%), MSFT (14.9%), GOOGL (13.1%), AMZN (10.9%), META (19.4%)
Rev Chg 3Y Avg3.0%NVDA (92.0%), MSFT (12.5%), GOOGL (10.2%), AMZN (11.3%), META (13.0%)
Op Mgn LTM27.9%NVDA (58.1%), MSFT (45.6%), AAPL (31.9%), GOOGL (32.7%), META (42.9%)
CFO/Rev LTM14.0%NVDA (46.6%), MSFT (48.3%), AAPL (26.6%), GOOGL (36.0%), AMZN (18.1%)
FCF/Rev LTM10.2%NVDA (43.6%), MSFT (25.4%), AAPL (23.5%), GOOGL (18.0%), META (30.7%)
Total Yield9.4%XOM (9.7%), BABA (38.9%), WFC (9.8%), TM (2104.3%), VZ (16.0%)

Latest Trefis Analyses

TitleTopicDate
0DASHBOARDS  
1Day 10 of Loss Streak for Edwards Lifesciences Stock with -8.2% Return (vs. 1.4% YTD) [9/16/2025]Notification 
2Day 9 of Loss Streak for Edwards Lifesciences Stock with -7% Return (vs. 2.7% YTD) [9/15/2025]Notification 
3Edwards Lifesciences Earnings Notes  
4Day 8 of Loss Streak for Edwards Lifesciences Stock with -5.1% Return (vs. 4.8% YTD) [9/12/2025]Notification 
5Day 6 of Gains Streak for Edwards Lifesciences Stock with 5.8% Return (vs. 9.9% YTD) [8/20/2025]Notification 
6Edwards Lifesciences vs Alphabet: Which Is A Better Investment?Counter-Intuitive Comparisons 
7Edwards Lifesciences vs ResMed: Which Is A Better Investment?Counter-Intuitive Comparisons 
8How Does EW Stack Up Against Its Peers?Peer Comparison 
9Better Bet Than EW Stock: Pay Less Than Edwards Lifesciences To Get More From GOOGL, META   
10Better Bet Than EW Stock: Pay Less Than Edwards Lifesciences To Get More From LLY, MCK   
11ARTICLES  
12EW Stock Down -8.2% after 10-Day Loss Streak September 17th, 2025
13EW Stock Down -7% after 9-Day Loss Streak September 16th, 2025
14EW Stock Down -5.1% after 8-Day Loss Streak September 13th, 2025
15EW Stock Up 5.8% after 6-Day Win Streak August 21st, 2025
16IDXX’s 22% One Month Pop Begs The Question: Is EW Better Instead? August 12th, 2025
Title
0DASHBOARDS
1EW Stock Down -8.2% after 10-Day Loss Streak
2EW Stock Down -7% after 9-Day Loss Streak
3EW Stock Down -5.1% after 8-Day Loss Streak
4EW Stock Up 5.8% after 6-Day Win Streak
5IDXX’s 22% One Month Pop Begs The Question: Is EW Better Instead?
6ARTICLES
7Day 10 of Loss Streak for Edwards Lifesciences Stock with -8.2% Return (vs. 1.4% YTD) [9/16/2025]
8Day 9 of Loss Streak for Edwards Lifesciences Stock with -7% Return (vs. 2.7% YTD) [9/15/2025]
9Edwards Lifesciences Earnings Notes
10Day 8 of Loss Streak for Edwards Lifesciences Stock with -5.1% Return (vs. 4.8% YTD) [9/12/2025]
11Day 6 of Gains Streak for Edwards Lifesciences Stock with 5.8% Return (vs. 9.9% YTD) [8/20/2025]
12Edwards Lifesciences vs Alphabet: Which Is A Better Investment?
13Edwards Lifesciences vs ResMed: Which Is A Better Investment?
14How Does EW Stack Up Against Its Peers?
15Better Bet Than EW Stock: Pay Less Than Edwards Lifesciences To Get More From GOOGL, META 
16Better Bet Than EW Stock: Pay Less Than Edwards Lifesciences To Get More From LLY, MCK 

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1BDSXBiodesix1313.2%-78.6%
2CLSDClearside Biomedical954.0%-74.9%
3SDOTSadot624.1%-79.4%
4WLDSWearable Devices498.0%-30.0%
5CHEKCheck-Cap285.6%154.6%
6ATCHAtlasClear275.9%-91.0%
7HSDTHelius Medical Technologies262.5%-95.6%
8OPIOffice Properties Income Trust261.7%-13.4%
9FGIFGI Industries156.8%145.2%
10AIREReAlpha Tech154.0%-56.1%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1NAKAKindly MD-81.4% 
2ATYRaTyr Pharma-79.7%-70.2%
3LGCLLucas GC-73.6%-77.1%
4EPSMEpsium Enterprise-70.1% 
5BNGOBionano Genomics-59.4%-89.7%
6FAASDigiAsia-58.5%-87.2%
7QMMMQMMM-57.5%6775.0%
8VCIGVCI Global-56.9%-99.1%
9YYGHYY-56.6%-78.5%
10XAGELongevity Health-55.5%-86.1%

1 Month Top Gainers

#TickerCompany1M RtnYTD Rtn
1PMIPicard Medical11963.5%11963.5%
2GIBOGIBO9734.4% 
3CHSNChanson International7565.0%-99.3%
4LNZALanzaTech Global7287.5%-86.0%
5QMMMQMMM3031.7%6775.0%
6OESXOrion Energy Systems1497.9%22.9%
7CURXCuranex Pharmaceuticals1401.6%1401.6%
8ENTOEntero Therapeutics565.6%117.6%
9PTNMPitanium553.2% 
10WLDSWearable Devices449.5%-30.0%

1 Month Top Losers

#TickerCompany1M RtnYTD Rtn
1CJETChijet Motor-92.2%-95.0%
2STFSStar Fashion Culture-92.2%-97.8%
3ELPWElong Power-91.6%-76.7%
4NXTTNext Technology-89.6%-95.1%
5NAKAKindly MD-89.0% 
6BINIBollinger Innovations-88.9%-100.0%
7JEM707 Cayman-88.4%-98.2%
8YAASYouxin Technology-82.5%-98.3%
9NEONNeonode-82.0%-50.2%
10NVNOenVVeno Medical-81.5%-69.8%

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1BDSXBiodesix1313.2%-78.6%
2CLSDClearside Biomedical954.0%-74.9%
3SDOTSadot624.1%-79.4%
4WLDSWearable Devices498.0%-30.0%
5CHEKCheck-Cap285.6%154.6%
6ATCHAtlasClear275.9%-91.0%
7HSDTHelius Medical Technologies262.5%-95.6%
8OPIOffice Properties Income Trust261.7%-13.4%
9FGIFGI Industries156.8%145.2%
10AIREReAlpha Tech154.0%-56.1%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1NAKAKindly MD-81.4% 
2ATYRaTyr Pharma-79.7%-70.2%
3LGCLLucas GC-73.6%-77.1%
4EPSMEpsium Enterprise-70.1% 
5BNGOBionano Genomics-59.4%-89.7%
6FAASDigiAsia-58.5%-87.2%
7QMMMQMMM-57.5%6775.0%
8VCIGVCI Global-56.9%-99.1%
9YYGHYY-56.6%-78.5%
10XAGELongevity Health-55.5%-86.1%

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Edwards Lifesciences

Financials

EWABTBSXMDTZBHBAXMedian
NameEdwards .Abbott L.Boston S.MedtronicZimmer B.Baxter I. 
Mkt Price75.09132.7698.9894.1999.1223.8796.59
Mkt Cap44.1231.5146.5120.719.612.282.4
Rev LTM5,68543,10918,49434,2007,83410,88714,690
Op Inc LTM1,5887,5153,3886,6471,4753982,488
FCF LTM5786,7753,2345,3031,3842182,309
FCF 3Y Avg5995,9722,1144,9641,1736581,643
CFO LTM7959,0374,2857,1461,6637652,974
CFO 3Y Avg8678,1303,0146,6251,5121,1662,263

Growth & Margins

EWABTBSXMDTZBHBAXMedian
NameEdwards .Abbott L.Boston S.MedtronicZimmer B.Baxter I. 
Rev Chg LTM9.1%5.9%21.4%5.0%4.1%3.6%5.4%
Rev Chg 3Y Avg3.0%-1.5%14.6%3.3%4.3%-5.7%3.1%
Rev Chg Q11.9%7.4%22.8%8.4%7.0%4.3%7.9%
QoQ Delta Rev Chg LTM2.9%1.8%5.4%2.0%1.8%1.1%1.9%
Op Mgn LTM27.9%17.4%18.3%19.4%18.8%3.7%18.6%
Op Mgn 3Y Avg29.5%16.2%17.6%18.6%19.2%2.9%18.1%
QoQ Delta Op Mgn LTM0.2%0.6%-0.2%-0.1%-0.4%0.1%0.0%
CFO/Rev LTM14.0%21.0%23.2%20.9%21.2%7.0%20.9%
CFO/Rev 3Y Avg17.2%19.6%18.8%20.2%20.1%11.2%19.2%
FCF/Rev LTM10.2%15.7%17.5%15.5%17.7%2.0%15.6%
FCF/Rev 3Y Avg11.9%14.4%13.1%15.1%15.5%6.3%13.7%

Valuation

EWABTBSXMDTZBHBAXMedian
NameEdwards .Abbott L.Boston S.MedtronicZimmer B.Baxter I. 
Mkt Cap44.1231.5146.5120.719.612.282.4
P/S7.85.47.93.52.51.14.4
P/EBIT26.327.544.018.915.9382.726.9
P/E10.616.658.525.923.8-79.020.2
P/CFO55.525.634.216.911.816.021.3
Total Yield9.4%7.8%1.7%6.8%5.2%2.6%6.0%
Dividend Yield0.0%1.7%0.0%3.0%1.0%3.8%1.3%
FCF Yield 3Y Avg1.1%3.0%1.8%4.5%5.3%3.5%3.2%
D/E0.00.10.10.20.40.80.2
Net D/E-0.10.00.10.20.40.70.1

Returns

EWABTBSXMDTZBHBAXMedian
NameEdwards .Abbott L.Boston S.MedtronicZimmer B.Baxter I. 
1M Rtn-4.1%0.8%-4.1%1.3%-3.5%-0.6%-2.1%
3M Rtn2.5%0.8%-2.7%10.2%9.9%-19.7%1.6%
6M Rtn6.8%6.1%-0.2%3.8%-12.0%-30.0%1.8%
12M Rtn8.3%15.0%18.5%8.0%-7.1%-39.4%8.1%
3Y Rtn-19.6%35.4%137.4%15.3%-10.0%-55.5%2.6%
1M Excs Rtn-6.5%-1.7%-6.5%-1.2%-6.0%-3.0%-4.5%
3M Excs Rtn-9.1%-10.0%-12.0%-1.5%-2.0%-31.5%-9.6%
6M Excs Rtn-10.1%-11.5%-16.3%-13.9%-27.6%-47.1%-15.1%
12M Excs Rtn-7.9%-2.2%0.0%-9.9%-23.2%-56.1%-8.9%
3Y Excs Rtn-85.2%-32.7%68.1%-46.4%-73.9%-119.0%-60.2%

Comparison Analyses

Financials

$ Mil | FY: 12/312025Q22025Q12024Q42024Q32024Q22024Q12023Q42023Q32023Q22023Q12022Q42022Q3
Period End6/30/20253/31/202512/31/20249/30/20246/30/20243/31/202412/31/20239/30/20236/30/20233/31/202312/31/20229/30/2022
Filing Date8/6/20255/6/20252/28/202511/6/20247/31/20244/29/20242/12/202410/27/20237/28/20234/28/20232/13/202310/28/2022
Key Financials Quarterly            
Total Revenue1,5321,4131,3861,3541,3691,3301,2661,2431,2961,4604301,319
Ebitda469446484429414396297405421468232490
Operating Income431410353394375358357368384433197454
Net Income3303583863,071364352370385307340398344
EPS0.570.610.655.140.610.580.610.630.510.560.650.55
Key Financials TTM            
Total Revenue TTM5,6855,5225,4405,3205,2095,1355,2654,4284,5044,5824,4645,364
Ebitda TTM1,8281,7731,7231,5371,5131,5191,5911,5261,6101,6681,6781,976
Operating Income TTM1,5881,5321,4801,4841,4571,4671,5421,3821,4681,5291,5391,705
Net Income TTM4,1444,1784,1724,1561,4701,4141,4021,4311,3901,4891,5221,459
Growth Rates Quarterly            
Total Revenue Growth11.9%6.2%9.4%8.9%5.7%-8.9%194.6%-5.7%-5.7%8.8%-67.7%0.7%
EBITDA Growth13.2%12.6%62.8%5.9%-1.5%-15.3%28.0%-17.3%-12.2%-2.1%-56.2%14.0%
Operating Income Growth15.0%14.5%-1.0%7.1%-2.6%-17.3%81.0%-19.0%-13.5%-2.3%-45.8%14.7%
Net Income Growth-9.3%1.7%4.2%697.8%18.4%3.3%-7.2%12.1%-24.4%-8.9%18.8%1.0%
Margins Quarterly            
EBITDA Margin30.6%31.6%34.9%31.7%30.2%29.8%23.5%32.6%32.5%32.0%54.0%37.1%
Operating Income Margin28.1%29.0%25.5%29.1%27.4%26.9%28.2%29.6%29.7%29.6%45.8%34.4%
Net Income Margin21.5%25.3%27.8%226.7%26.6%26.5%29.2%31.0%23.7%23.3%92.7%26.0%
Cash & Debt            
Total Cash4,0623,8983,9764,4461,9901,6981,6331,8641,5091,2541,2151,739
Total Debt703699700707693699685691684688691687
Net Debt / (Cash)-3,360-3,199-3,276-3,739-1,297-998-948-1,173-825-566-524-1,052
Cash Flows Quarterly            
FCF from Operations290280-128352372-5413741234314283310
Cash Flows TTM            
FCF from Operations TTM7958765428068665288961,0429401,2391,2181,309
Returns to Shareholders Quarterly            
Dividends000000000000
Share Repurchases625910090115804481748249866100
Return on Invested Capital (ROIC) Quarterly            
ROIC------------
Return on Invested Capital (ROIC) TTM            
ROIC TTM------------

Segment Financials

Revenue by Segment

$ Mil20242023202220212020
Transcatheter Aortic Valve Replacement3,8803,5183,4222,8572,738
Surgical Structural Heart933830889762842
Transcatheter Mitral and Tricuspid Therapies198116864228
Critical Care  835725740
Total5,0104,4645,2324,3864,348


Price Behavior

EW Betas & Captures as of 8/31/2025

 1M2M3M6M1Y3Y
Beta0.090.430.520.530.530.71
Up Beta0.010.250.250.510.480.58
Down Beta0.080.040.490.490.470.60
Up Capture28%76%56%60%53%45%
Bmk +ve Days10223571142415
Stock +ve Days13233165125372
Down Capture-11%49%73%60%69%99%
Bmk -ve Days11192754106334
Stock -ve Days8183059121375

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Short Interest

Short Interest: As Of Date8292025
Short Interest: Shares Quantity10,351,625
Short Interest: % Change Since 815202527.2%
Average Daily Volume4,332,529
Days-to-Cover Short Interest2.39
Basic Shares Quantity587,000,000
Short % of Basic Shares1.8%

Returns Analyses

Earnings Returns History

Expand for More

 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
7/24/20255.5%4.6%8.0%
4/23/20256.6%7.1%6.1%
2/11/20256.9%5.3%-4.2%
10/24/2024-1.4%-4.7%0.2%
4/25/2024-1.8%-3.4%-0.0%
2/6/2024-1.9%-2.3%6.3%
10/25/2023-8.1%-6.6%-0.6%
7/26/2023-9.8%-12.3%-18.1%
...
SUMMARY STATS   
# Positive111211
# Negative121112
Median Positive1.6%4.1%4.6%
Median Negative-5.8%-4.7%-6.1%
Max Positive6.9%7.3%8.0%
Max Negative-17.9%-20.4%-18.1%

SEC Filings

Expand for More

Report DateFiling DateFiling
6302025806202510-Q 6/30/2025
3312025506202510-Q 3/31/2025
12312024228202510-K 12/31/2024
93020241106202410-Q 9/30/2024
6302024731202410-Q 6/30/2024
3312024429202410-Q 3/31/2024
12312023212202410-K 12/31/2023
93020231027202310-Q 9/30/2023
6302023728202310-Q 6/30/2023
3312023428202310-Q 3/31/2023
12312022213202310-K 12/31/2022
93020221028202210-Q 9/30/2022
6302022729202210-Q 6/30/2022
3312022428202210-Q 3/31/2022
12312021214202210-K 12/31/2021
93020211029202110-Q 9/30/2021

Insider Activity

Expand for More

 OwnerTitleFiling DateActionPriceSharesTransacted
Value		Value of
Held Shares		Form
0Chopra DaveenCVP, TMTT8252025Sell81.952,500204,8652,539,998Form
1Lippis Daniel J.CVP, JAPAC7282025Sell79.464,114326,9001,748,283Form
2Zovighian Bernard JCEO6032025Sell77.2116,0991,243,065738,438Form
3BOBO DONALD E JRCVP,Strategy/Corp Development6022025Sell77.402,570198,9113,897,452Form
4Chopra DaveenCVP, TMTT5222025Sell75.081,500112,6122,514,712Form

Industry Resources

External Quote Links


Prefer one of these to Trefis? Tell us why.